1. Home
  2. KEQU vs RNTX Comparison

KEQU vs RNTX Comparison

Compare KEQU & RNTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Kewaunee Scientific Corporation

KEQU

Kewaunee Scientific Corporation

N/A

Current Price

$36.40

Market Cap

110.9M

Sector

Industrials

ML Signal

N/A

Logo Rein Therapeutics Inc.

RNTX

Rein Therapeutics Inc.

HOLD

Current Price

$0.86

Market Cap

89.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
KEQU
RNTX
Founded
1906
2001
Country
United States
United States
Employees
N/A
10
Industry
Medical Specialities
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
110.9M
89.0M
IPO Year
1995
N/A

Fundamental Metrics

Financial Performance
Metric
KEQU
RNTX
Price
$36.40
$0.86
Analyst Decision
Buy
Analyst Count
0
2
Target Price
N/A
$10.00
AVG Volume (30 Days)
5.8K
579.2K
Earning Date
03-11-2026
05-15-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
3.22
N/A
Revenue
$138,558,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$11.30
N/A
Revenue Growth
7.72
N/A
52 Week Low
$33.27
$0.83
52 Week High
$60.89
$2.18

Technical Indicators

Market Signals
Indicator
KEQU
RNTX
Relative Strength Index (RSI) 50.20 40.62
Support Level $35.15 $0.85
Resistance Level $38.53 $1.05
Average True Range (ATR) 1.14 0.07
MACD 0.10 -0.01
Stochastic Oscillator 38.82 14.18

Price Performance

Historical Comparison
KEQU
RNTX

About KEQU Kewaunee Scientific Corporation

Kewaunee Scientific Corp is a designer and manufacturer of technical furniture products for industries investing in spaces where discovery occurs, typically in laboratories. It serves in end-use markets that are all commercial, Life sciences, pharma, education, government and military research, etc. The company operates through two segments: The domestic segment designs manufactures and installs scientific and technical furniture, including steel and wood laboratory cabinetry, fume hoods, laminate casework, flexible systems, and Others; The International segment provides facility design, engineering, construction, and project management from the planning stage through the testing and commissioning of laboratories. It generates the majority of its revenue from the Domestic business segment.

About RNTX Rein Therapeutics Inc.

Rein Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing novel therapies for the treatment of orphan pulmonary and fibrosis indications with no approved or limited effective treatments. Its pipeline includes: LTI-03, a peptide, for placebo-controlled safety, tolerability, and pharmacodynamic biomarker activity trial in development for the treatment of Idiopathic Pulmonary Fibrosis, that has demonstrated the ability to protect healthy lung epithelial cells and reduce pro-fibrotic signaling; LTI-01, a proenzyme that completed a Phase 2a dose-ranging, placebo-controlled trial and a Phase 1b safety, tolerability and proof of mechanism trial in loculated pleural effusion, or LPE, patients, an indication that has no approved drug treatment.

Share on Social Networks: